Stricker will work with practices to reduce the burden of physicians ordering and interpreting genomic tests.
1) To ensure the correct tests are ordered.
2) On preliminary results to ensure that appropriate therapy is given based on current data.
3) To identify additional options, whether standard treatments or clinical trial options, in case of relapse or progression.
“The complexity of pathological standards in oncology requires changes in the way results are delivered, such as comprehensive reports that summarize key data from multiple studies,” said Dr. Striker. “I look forward to helping develop a system that will enable our physicians to maximize the value of testing at every stage.”
dr Stryker was most recently an assistant professor in the Department of Pathology, Microbiology, and Immunology at Vanderbilt University, where he founded the Somatic Clinical Sign-Out Team and the Clinical Genomics Lab, which creates whole exome and other germline sequencing panels. dr Stryker was also associate director of Vantage, Vanderbilt’s research sequencing center.
At Vanderbilt, Dr. Stryker also serves on the Molecular Tumor Boards and was part of the team that established GENIE, an initiative of the American Association for Cancer Research, to share cancer genomic sequencing data between institutions. dr Stricker has extensive experience in the preparation and analysis of next-generation sequencing data and in the creation and signing of clinical genome reports.
“DR. Stryker brings extensive experience in genome sequencing, research and data integration across cancer institutions,” said Davy Daniels, MD, Chief Medical Officer of OneOncology support the use of genomic testing to match the right treatment or test at the right time – in all oncology practices that can conveniently live closer to the patient.”
dr Stryker earned his MD and PhD from Washington University in St. Louis. After a residency in Anatomical Pathology and a Bone and Soft Tissue Fellowship at the University of Chicago, he joined the lab of Dr. Kevin White at the Institute of Genomics and Systems Biology. There he developed expertise in the generation and analysis of data from the then new next-generation sequencing technologies.
OneOncology was founded by community oncologists for community oncologists with a mission to improve the lives of everyone living with cancer. Our goal is to enable community oncology practices to remain independent and improve patient access to care in their communities at a lower cost than hospitals. OneOncology Group supports our collaborative oncology practice platform through sourcing, operations optimization, practice development and clinical innovation. Our 700 cancer care providers serve 280,000 patients at 181 care locations nationwide. To learn more, visit oneoncology.com or LinkedIn,